This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harding, M., Cantwell, B., Milstead, R. et al. Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer. Br J Cancer 57, 628–629 (1988). https://doi.org/10.1038/bjc.1988.143
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.143
This article is cited by
-
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates
Investigational New Drugs (2006)
-
TomudexTM (ZD1694): from concept to care, a programme in rational drug discovery
Investigational New Drugs (1996)
-
Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells
Cancer Chemotherapy and Pharmacology (1994)